Every material Form 8-K Cartesian Therapeutics, Inc. has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Cartesian Therapeutics reported a third-quarter 2026 net loss of $11.5 million, or $0.38 per share, down from $35.9 million, or $1.38 per share, a year earlier. The narrower loss came mainly from a $10.7 million gain on the contingent value rights liability, while operating loss widened and revenue fell to zero, so the results are mixed for shareholders.
Net loss was $11.5 million ($0.38 per share) versus $35.9 million ($1.38 per share) a year earlier; the CVR liability produced a $10.7 million gain, compared with a $16.9 million loss in the prior-year quarter.
Operating loss widened to $25.0 million from $21.1 million, as research and development expenses rose to $15.6 million from $13.8 million and general and administrative expenses rose to $9.4 million from $7.7 million.
Revenue was zero in the quarter, compared with $452,000 a year earlier.
Cash, cash equivalents and restricted cash were $124.7 million at September 30, 2026, expected to support planned operations into 2028; Phase 3 AURORA data are expected in 1Q27 and a BLA is planned for mid-2027.
Cartesian Therapeutics presented 12-month data from five Phase 2 patients with myasthenia gravis who were retreated with Descartes-08 after symptoms returned. The company said retreated patients showed a mean MG-ADL reduction of 6.6 points at Month 12 and no serious adverse events during retreatment, and it reiterated that Phase 3 AURORA topline data are expected in the first quarter of 2027.
Five retreated patients; median interval of 16.6 months from end of initial treatment course to retreatment
Average MG-ADL reduction of 6.6 (±4.2) points and MGC reduction of 15 (±6.2) points from baseline at Month 12
No serious adverse events reported during retreatment; no cases of cytokine release syndrome or ICANS
Phase 3 AURORA topline data expected in 1Q27; BLA filing expected in mid-2027
Cartesian Therapeutics reported second quarter 2026 results with net income of $15.8 million, or $0.47 per basic share, roughly flat with $15.9 million, or $0.51 per share, a year earlier. The result relied on a $49.2 million gain on the contingent value rights liability, while the operating loss widened to $29.2 million from $21.8 million as research and development and general and administrative expenses rose.
Q2 2026 net income $15.8 million ($0.47 basic EPS) vs. $15.9 million ($0.51) in Q2 2025.
Operating loss $29.2 million vs. $21.8 million; R&D expenses $20.4 million vs. $14.9 million.
Revenue was zero in Q2 2026 vs. $298,000 in Q2 2025.
Cash, cash equivalents and restricted cash $149.3 million at June 30, 2026, expected to support operations into 2028.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Cartesian Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →